Tesamorelin reduced belly fat without affecting other fat or weight in HIV patients with abdominal obesity.

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.